List of Figures

Figure 1: Types of Cancer Treatment
Figure 2: Timeline for Intratumoral Immunotherapy
Figure 3: Intratumoral Immunotherapy Mechanisms and Invoking an Abscopal Effect
Figure 4: Principles of Intratumoral Immunotherapy
Figure 5: Classification of the Different Types of Immunotherapy Agents
Figure 6: Global Heat Map of all cancers in 2020, both sexes, all ages
Figure 7: Total incident cases of selected cancer types across the 7MM (2019–2032)
Figure 8: Target patient Pool of Intratumoral therapies by Cancer Types across the 7MM (2019–2032)
Figure 9: Treated cases by Cancer Types across the 7MM (2019–2032)
Figure 10: Total Incident cases of selected cancer types across the US (2019–2032)
Figure 11: Target patient Pool of Intratumoral therapies by Cancer Types across the US (2019–2032)
Figure 12: Treated cases by Cancer Types in the US (2019–2032)
Figure 13: Total Incident cases of selected cancer types in EU5 (2019–2032)
Figure 14: Target patient Pool of Intratumoral therapies by Cancer Types across EU5 (2019–2032)
Figure 15: Treated cases by Cancer Types across EU5 (2019–2032)
Figure 16: Total Incident cases of selected cancer types in Japan (2019–2032)
Figure 17: Target patient Pool of Intratumoral therapies by Cancer Types in Japan (2019–2032)
Figure 18: Treated cases by Cancer Types across the 7MM in Japan (2018–2032)
Figure 19: Intratumoral Immunotherapy Clinical Trials
Figure 20: Mechanism of Action
Figure 21: Structure of DNX-2401 (tasadenoturev)
Figure 22: Market Size of Intratumoral Cancer Therapies in the 7MM, USD Million (2019–2032)
Figure 23: Market Size of Intratumoral Cancer Therapies By Indications in the 7MM, USD Million (2019–2032)
Figure 24: 7MM Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Figure 25: Market Size of Intratumoral Cancer Therapies in the US, USD Million (2019–2032)
Figure 26: Market Size of Intratumoral Cancer Therapies By Indications in the US, USD Million (2019–2032)
Figure 27: US Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Figure 28: Market Size of Intratumoral Cancer Therapies in EU5, USD Million (2019–2032)
Figure 29: Market Size of Intratumoral Cancer Therapies By Indications in the EU5, USD Million (2019–2032)
Figure 30: EU5 Therapywise market size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Figure 31: Market Size of Intratumoral Cancer Therapies in Japan, USD Million (2019–2032)
Figure 32: Market Size of Intratumoral Cancer Therapies By Indications in Japan, USD Million (2019–2032)
Figure 33: Japan Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)

List of Tables

Table 1: Summary of Intratumoral Cancer Therapy: Market, Epidemiology, and Key Events (2019–2032)
Table 2: Factors Affecting Transport of Therapy Out of the Tumor After Intratumoral Injection and Probable Transport Phenomena
Table 3: Categories of Intratumoral Therapies to Treat Cancer
Table 4: Intratumoral Immunotherapy: Universal Rather than Personalized Cancer Immunization
Table 5: Incident cases (2020) and Year-over-year (YOY) cancer growth rates
Table 6: Total incident cases of selected cancer types across the 7MM (in Thousands) (2019–2032)
Table 7: Target patient Pool of Intratumoral therapies by Cancer Types across the 7MM (in Thousands) (2019–2032)
Table 8: Treated cases by Cancer Types across the 7MM (in Thousands) (2019–2032)
Table 9: Total Incident cases of selected cancer types across the US (in Thousands) (2019–2032)
Table 10: Target patient Pool of Intratumoral therapies by Cancer Types across the 7MM (in Thousands) (2019–2032)
Table 11: Treated cases by Cancer Types across the US (in Thousands) (2019–2032)
Table 12: Total Incident cases of selected cancer types across EU5 (in Thousands) (2019–2032)
Table 13: Treated cases by Cancer Types across EU5 (in Thousands) (2019–2032)
Table 14: Total Incident cases of selected cancer types in Japan (in Thousands) (2019–2032)
Table 15: Target patient Pool of Intratumoral therapies by Cancer Types in Japan (in Thousands) (2019–2032)
Table 16: Treated cases by Cancer Types in Japan (in Thousands) (2019–2032)
Table 17: Summary of Results for the ITT Population From IMLYGIC Study 005/05
Table 18: IMLYGIC, Clinical Trial Description, 2022
Table 19: Results on Tumor Reduction Effect and Safety
Table 20: HENSIFY (NBTXR3), Clinical Trial Description, 2022
Table 21: STP705; Clinical Trial Description, 2022
Table 22: APX005M; Clinical Trial Description, 2022
Table 23: RP1; Clinical Trial Description, 2022
Table 24: V937; Clinical Trial Description, 2022
Table 25: BO-112, Clinical Trial Description, 2022
Table 26: Tavokinogene telseplasmid (tavo); Clinical Trial Description, 2022
Table 27: INT230-6; Clinical Trial Description, 2022
Table 28: DNX-2401; Clinical Trial Description, 2022
Table 29: G207; Clinical Trial Description, 2022
Table 30: NIDLEGY (daromun; L19IL2 + L19TNF), Clinical Trial Description, 2022
Table 31: LOAd703, Clinical Trial Description, 2022
Table 32: Vidutolimod (CMP-001); Clinical Trial Description, 2022
Table 33: PVSRIPO; Clinical Trial Description, 2022
Table 34: 7MM Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 35: 7MM Market Size of Intratumoral Cancer Therapies By Indications in USD Million (2019–2032)
Table 36: 7MM Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 37: US Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 38: US Market Size of Intratumoral Cancer Therapies By Indications in USD Million (2019–2032)
Table 39: US Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 40: EU5 Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 41: EU5 Market Size of Intratumoral Cancer Therapies By Indications in USD Million (2019–2032)
Table 42: EU-5 Market Size of Intratumoral Cancer Therapies by Therapies in USD Million (2018–2032)
Table 43: Japan Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 44: Japan Market Size of Intratumoral Cancer Therapies By Indications in USD Million (2019–2032)
Table 45: Japan Market Size of Intratumoral Cancer Therapies in USD Million (2019–2032)
Table 46: NICE Assessment for Intra-tumoral Therapies